Strongbridge Biopharma plc to Present at Two Upcoming Investor Conferences

Article Stock Quotes (1)

FREE Breaking News Alerts from StreetInsider.com!

StreetInsider.com Top Tickers, 8/18/2026

1. NVDA
2. HD
3. AMLX
4. METC
5. SPY

6. DOO
7. ARGX
8. INFQ

Get Alerts SBBP Hot Sheet

Price: $2.00 --0%

Overall Analyst Rating:
SELL (= Flat)

Join SI Premium – FREE

DUBLIN, Ireland and TREVOSE, Pa., Nov. 12, 2019 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc, (Nasdaq: SBBP), a global commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with significant unmet needs, today announced that John H. Johnson, executive chairman, will present at the Stifel 2019 Healthcare Conference and the Evercore ISI 2nd Annual HealthCONx Conference. The details of the conferences are as follows:

Stifel 2019 Healthcare Conference Tuesday, November 19 at 4:10 pm ET Lotte New York Palace Hotel, New York, NY

Evercore ISI 2nd Annual HealthCONx ConferenceTuesday, December 3 at 9:30 am ETFour Seasons Hotel, Boston, MA

The Company’s presentation will be webcast live and archived on the “Events & Presentations” page in the Investor section of the Company’s website at www.strongbridgebio.com.

About Strongbridge BiopharmaStrongbridge Biopharma is a global commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with significant unmet needs. Strongbridge’s rare endocrine franchise includes RECORLEV™ (levoketoconazole), a cortisol synthesis inhibitor currently being studied in Phase 3 clinical studies for the treatment of endogenous Cushing’s syndrome, and veldoreotide extended release, a pre-clinical next-generation somatostatin analog being investigated for the treatment of acromegaly and potential additional applications in other conditions amenable to somatostatin receptor activation. Both RECORLEV and veldoreotide have received orphan drug designation from the FDA and the European Medicines Agency. The Company’s rare neuromuscular franchise includes KEVEYIS® (dichlorphenamide), the first and only FDA-approved treatment for hyperkalemic, hypokalemic, and related variants of primary periodic paralysis. KEVEYIS has orphan drug exclusivity in the United States.

Contacts:Corporate and Investor Relations Strongbridge Biopharma plc Marcy Nanus +1 484-312-3744[email protected]

Media Relations Elixir Health Public Relations Lindsay Rocco +1 862-596-1304[email protected]